PB 127

Drug Profile

PB 127

Alternative Names: CardioSphere; CARDIOsphere; PBC 127

Latest Information Update: 08 Jun 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator POINT Biomedical
  • Class Albumins; Contrast media; Polyesters
  • Mechanism of Action Ultrasonography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cardiomyopathies

Most Recent Events

  • 27 Feb 2006 The US FDA has accepted the NDA for PB 127 for review
  • 09 Jan 2006 Preregistration for Cardiomyopathy (diagnosis) in USA (unspecified route)
  • 04 Mar 2004 Data from a media release have been added to the adverse events and Heart Failure therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top